TrialAntimicrobial agents and chemotherapy2009

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Constance Delaugerre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.